Biohaven Pharmaceuticals

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases. The Company has two small molecule calcitonin gene-related peptide (CGRP) receptor antagonist product candidates in development, rimegepant and vazegepant, for acute and preventive treatment of migraine. Rimegepant, the lead candidate, is an orally-administered, rapidly dissolving single dose CGRP with a novel mechanism that targets the underlying pathophysiology of migraine without causing vasoconstriction. For more information, visit www.biohavenpharma.com.